Today is World Arthritis Day and although events in North America seem to be few and far between, take a look at what is happening around the world at World Arthritis Day Link
Over the past two years, the Food and Drugs Act Liaison Office (FDALO) has:
- given a voice to stakeholders who have had difficulty being heard by the department;
- helped staff build competencies in better managing difficult relations with stakeholders;
- promoted openness and transparency in the regulatory process; and
- provided feedback on trends to contribute to the continuous business improvement of regulatory processes under the Food and Drugs Act.
This report presents an overview of FDALO's activities during its first two years in operation and sets out key objectives for the way forward.
See the report at: FDALO Report on Activities 2008-10
CAPA along with The Arthritis Society is asking patients for their input into their experience with a new drug for Gout.
A second drug indicated for arthritis (gout) - Febuxostat/Uloric (manufactured by Takeda) - is up for Common Drug Review consideration. This has triggered a request for submissions from registered patient groups. The Arthritis Society will be making a submission.
CAPA Members (and Concerned Canadians) are requested to help identify people who have had experience with this new drug or who have experience with gout and to ask them to provide input. The deadline for submission is Nov. 15 so to allow time for the submission to be prepared in the required format TAS will **need the input by Nov. 2. **
If you can help with this (or can forward this to people who are interested), please read the attached and respond directly to: